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The present case–control study was to investigate the relationships of plasma leptin level and anthropometric measures of adiposity
with the risk of breast cancer. Questionnaire information, anthropometric measures and blood samples were taken before treatment
from 297 incident cases with breast cancer and 593 controls admitted for health examination at the Tri-Service General Hospital,
Taipei, between 2004 and 2006. Plasma levels of leptin were measured by RIA. Logistic regression analysis was used to estimate odds
ratios (ORs) and 95% confidence intervals (CIs) for assessing the associations. Overall, higher leptin concentrations were significantly
associated with an increased risk of breast cancer (OR (95% CI) for top vs bottom tertile of leptin was 1.63 (1.07–2.49),
Ptrend¼0.009). Waist circumference was a significant anthropometric factor for breast cancer in both pre- and postmenopausal
women. Furthermore, the associations of leptin with breast cancer risk remained after adjustment for obesity indices. These results
suggest that leptin may have an independent role in breast tumorigenesis. Regardless of the impact of circulating leptin, more research
is needed to elucidate molecular mechanisms and local leptin levels that are critical for the development of breast cancers.
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Epidemiologic evidence suggested that obesity is associated with
an increased risk of breast cancer in women, primarily in
postmenopausal population (Calle and Thun, 2004). However,
the molecular mechanisms underlying the obesity–breast cancer
link are not fully clear. One important factor contributing to
obesity–breast carcinogenesis might be an excess exposure of
mammary epithelium to various bioactive substances produced by
the adipose tissue (adipokines). Indeed, adipose tissue is a source
of oestrogens, insulin and insulin-like growth factors, all of which
are believed to be involved in mammary tumorigenesis (Scha ¨ffler
et al, 2007). The most prominent adipokine is leptin, which is best
known as a regulator of food intake and energy balance in the
hypothalamus (Auwerx and Staels, 1998). Interestingly, leptin is
also implicated in the regulation of reproductive hormones
and function (Zhang et al, 2005). Notably, leptin consistently
stimulates the proliferation of benign and malignant epithelial
breast cells in vitro as measured by DNA synthesis and
upregulation of downstream regulators of cellular proliferation
(Dieudonne et al, 2002; Hu et al, 2002). Thus, the intriguing
possibility exists that leptin could be directly related to breast
carcinogenesis by underlying the effects of obesity on cancer
development. We have undertaken a case–control study to test
this hypothesis.
MATERIALS AND METHODS
Case and control selection
This case–control study was conducted at the Tri-Service General
Hospital, Taipei, Taiwan, from January 2004 to November 2006. To
account for the notions that type 2 diabetes and metabolic
syndrome (MS) have been associated with increased serum leptin
levels and elevated risk of breast cancer (Vona-Davis et al, 2007),
individuals with a history of type 2 diabetes and/or MS were
excluded from this study. On the basis of the hospital chart
number, the cases involved 297 women consecutively selected from
subjects with a first confirmed histopathologic diagnosis of breast
carcinoma in the age range of 24–72 years. The histopathological
profile included 216 cases of invasive ductal carcinoma, 31 cases of
mucinous carcinoma or invasive lobular carcinoma and 50 cases of
carcinoma in situ. There were 172 premenopausal and 125
postmenopausal cases with breast cancer. Control subjects
comprising individuals without a history of cancer were simulta-
neously recruited from the health examination clinics of the same
hospital during the same study period. Two control subjects were
matched to each case by date of enrolment (±3 months) and
duration of fasting (±4h). One control subject with inadequate
specimen was excluded, resulting in 297 cases and 593 controls
included in this study.
Collection of questionnaire data and blood specimens
Once case patients and control subjects agree to participate,
written informed consent was obtained from all the subjects. The
research protocol was approved by the Institutional Review Board
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sat the Tri-Service General Hospital, Taipei. All participants
underwent personal interview administered by well-trained inter-
viewers in conformance with institutional guidelines for studies
including human subjects. Data were collected on sociodemo-
graphic characteristics, menstrual and reproductive history,
menopausal status, lifestyle behaviours and medical history as
well as family history of breast and other cancers. More
specifically, in this study, menopausal status was defined as last
menstruation after 1 year free of menstrual cycle, and no attempt
was made to distinguish between women with artificial and those
with natural menopause. Immediately after the interview, a 10-ml
blood sample was drawn into coded EDTA-treated tubes and
centrifuged at 1467g for 10min at room temperature within 10h of
collection. Plasma, buffy coat and red blood cells were separated
and stored at  701C until subsequent analysis. In this study,
efforts had been made to obtain questionnaire data and bio-
specimens before cases’ acceptance with surgery and/or receiving
adjuvant therapy, any influence of treatment protocol being
unlikely.
Anthropometric measurements and laboratory analysis of
plasma leptin levels
Participants reported information regarding height and weight.
Body mass index (BMI), as an indicator of generalised obesity, was
calculated as weight in kilograms divided by the square of height in
metres. In addition, the measurements of waist and hip
circumferences were performed by trained clinical staff using
standardised techniques. Waist girth was determined with a
measuring tape placed horizontally around the midpoint between
the iliac crest and lower margin of the ribs. Hip girth was the
maximum circumference around the buttocks posteriorly and the
symphysis pubis anteriorly. As a result, waist circumference (WC)
and waist-to-hip ratio (WHR) represent a measure of central
adiposity. Plasma leptin concentrations were measured in a single
run using a commercially available RIA kit (Linco Research Inc.,
Missouri, MO, USA) according to the manufacturer’s instructions.
The sensitivity of this assay is 0.5ngml
 1; the intraassay
coefficient of variation being 4.98% and the interassay coefficient
of variation being 4.5%. Leptin is extremely stable and can be
stored at  201C for prolonged periods of time and even at 41Co r
room temperature for several days without significant degradation
(Ma et al, 1996). All matched case–control blood samples were
handled identically and assayed in the same analytical run. The
blood samples were labelled by number only and ordered
randomly within each case–control pair. Accordingly, laboratory
personnel were unaware of the case–control status.
Statistical analysis
Differences between cases and controls in age at menarche, age at
first full-term pregnancy (FFTP), age at menopause and parity
numbers were tested using the Student’s t-test. Spearman
correlation coefficients were used to examine cross-sectional
relationships between leptin and anthropometric measures of
adiposity. In addition, conditional logistic regression, which
preserves the matching of cases and controls, was used to estimate
odds ratios (ORs) and 95% confidence intervals (CIs) for the
associations between plasma leptin levels and anthropometric
measures and breast cancer risk.
RESULTS
The baseline characteristics of cases and controls are summarised
in Table 1. The mean age (±s.d.) of the cases and controls was 49.7
(±8.7) and 48.7 (±8.5) years, respectively. There were no
statistically significant differences between cases and controls in
terms of age at menarche (13.6 vs 13.7 years), age at FFTP (26.7 vs
26.5 years), age at menopause (48.9 vs 48.5 years) and parity
number (2.0 vs 2.0). By contrast, there were statistically significant
differences between cases and controls for anthropometric
measures of adiposity. The average BMI, WC and WHR
were higher in breast cancer cases than in control subjects (23.4
vs 22.9kgm
 2, P¼0.0648; 77.7 vs 75.1cm, Po0.0001; and 0.81 vs
0.78, Po0.0001, respectively).
To assess the relationship of plasma leptin levels with
anthropometric measures of adiposity, we performed a correlation
analysis among control subjects. As expected, plasma leptin was
significantly positively correlated with BMI (r¼0.59, Po0.0001),
WC (r¼0.50, Po0.0001) and WHR (r¼0.23, Po0.0001). The
mean (±s.d.) levels of leptin in cases with invasive breast cancer,
patients with carcinoma in situ and control subjects were
10.4(±7.0), 8.7(±5.3) and 8.4 (±5.3ngml
 1), respectively. We
further categorised plasma leptin either as high or as low levels
(based on the 75 percentile in the control group) or into three
groups (based on the tertile values in the control group) when
appropriate for subsequent analyses. Table 2 presents the risk of
breast cancer in relation to plasma leptin levels. Overall, higher
leptin concentrations were statistically significantly associated with
an increased risk of breast cancer. Compared with those in the
lowest tertile, the ORs of breast cancer for women in the second
and third tertiles were 0.93 (95% CI¼0.63–1.38) and 1.63 (95%
CI¼1.07–2.49), respectively (Ptrend¼0.0091). In subgroup ana-
lyses according to menopausal status, a similar pattern regarding
breast cancer risk associated with higher levels of leptin was
observed in postmenopausal women. Additional adjustment for
BMI and WC slightly attenuated these associations. Restricting
analysis to cases with invasive cancers and control subjects did not
reveal any other remarkable discrepancies in results (data not
shown). Concerning the roles of general and central obesity, we
found that increasing BMI values were associated with reduced
risk of breast cancer in premenopausal women after adjustment
for circulating leptin levels (OR¼0.22; 95% CI¼0.10–0.48
for the highest vs the lowest tertile; Ptrend¼0.001), whereas an
increasing WC was associated with increased risk of breast cancer
in both pre- and postmenopausal women when an adjustment for
leptin concentrations was made (ORs (95% CI) for the highest vs
the lowest tertile in pre- and postmenopausal women were 3.54
(1.55–8.10) and 2.85 (1.19–6.84), respectively). Accordingly, WC
was a significant anthropometric factor for breast cancer. Thus, we
further evaluate the possible joint effect of WC and leptin on breast
cancer risk for the whole group and separately for pre- and
postmenopausal women (Table 3). In general, the highest risk was
observed for those who had higher WC measures and elevated
circulating leptin levels. When compared with risks for women
with WC measures and leptin concentrations less than the third
tertiles, the ORs (95% CI) for those who had WC measures and
plasma leptin levels in the highest tertiles for the whole group and
Table 1 Characteristics of breast cancer cases and their matched
controls
Baseline
characteristics
Cases
(n¼297)
Controls
(n¼593) P-value
Age (year) 49.66±8.72 48.71±8.51 0.1196
Age at menarche (year) 13.64±1.50 13.67±1.53 0.7624
Age at FFTP (year) 26.72±4.14 26.46±4.05 0.4049
Age at menopause (year) 48.89±5.15 48.48±4.82 0.4466
Number of parity 2.01±1.15 2.02±1.08 0.9314
BMI (kgm
 2) 23.36±4.00 22.88±2.93 0.0648
Waist circumference (cm) 77.67±9.37 75.13±7.56 o0.0001
WHR 0.81±0.06 0.78±0.05 o0.0001
BMI¼body mass index; FFTP¼first full-term pregnancy; WHR¼waist-to-hip ratio.
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sseparately for pre- and postmenopausal women were 2.51
(1.51–4.19), 1.99 (1.06–3.39) and 3.25 (1.53–6.91), respectively.
DISCUSSION
Leptin is a peptide hormone that is mainly synthesised and
secreted by the adipose tissue (Considine et al, 1996; Auwerx and
Staels, 1998). The plasma leptin concentrations increased in direct
proportion to the adipose mass (Considine et al, 1996; Zhang et al,
2005). Although leptin has been viewed as the hormonal signal for
the regulation of energy homoeostasis (Auwerx and Staels, 1998),
several lines of evidence suggest that leptin plays a much broader
physiological role (Rosenbaum and Leibel, 1999; Zhang et al,
2005). On a cellular level, leptin has been found to act as a
metabolic regulator and motogenic and pro-angiogenic factors
(Sierra-Honignann et al, 1998; Hardwick et al, 2001; Hu et al, 2002;
Chio et al, 2004; Yin et al, 2004; Chen et al, 2006a). In addition,
new evidence suggests that leptin could be involved in tumori-
genesis, especially in the development of breast, colorectal and
prostate cancers (Garofalo and Surmacz, 2006).
In this study, we found a significant increase in the risk of breast
cancer associated with a high plasma level of leptin. Intriguingly,
women in the intermediate tertile of leptin had a nonsignificantly
reduced risk for breast cancer compared with those in the lowest
tertile. The reasons for this observation are unclear and may reflect
the play of chance. Although leptin has been shown to be
correlated with breast cancer risk in this study and earlier reports
(Tessitore et al, 2004; Han et al, 2005; Chen et al, 2006b; Hou et al,
2007; Liu et al, 2007), contradictory results were also documented
by other investigators. Some reports suggested a negative
correlation between leptin and breast cancer in the premenopausal
but not postmenopausal group (Petridou et al, 2000), whereas
several authors described that there was no significant association
between circulating leptin and breast cancer risk (Mantzoros et al,
1999; Coskun et al, 2003; Sauter et al, 2004; Stattin et al, 2004;
Woo et al, 2006). The inconsistent data obtained with circulating
leptin and breast cancer risk could be, at least in part, explained by
differences in sample preparation and measurement techniques as
well as the lack of control for potential factors that influence leptin
concentrations, such as food intake. Indeed, the hypothesis that
leptin is mechanistically related to the development of breast
Table 3 Joint effect of WC status and plasma leptin levels on breast cancer risk
Group WC
a (cm) Leptin
a (ngml
 1) No. of cases (%) No. of controls (%) OR
b (95% CI) Ptrend
All women
p80 p10.9 153 (51.9) 375 (63.8) 1.00 (reference)
p80 410.9 45 (15.2) 65 (11.0) 2.00 (1.27–3.17)
480 p10.9 38 (12.9) 71 (12.1) 1.65 (0.99–2.76)
480 410.9 59 (20.0) 77 (13.1) 2.51 (1.51–4.19) 0.0006
Premenopausal
p80 p10.6 110 (64.0) 214 (64.5) 1.00 (reference)
p80 410.6 25 (14.5) 35 (10.5) 1.90 (0.98–4.02)
480 p10.6 10 (5.8) 37 (11.1) 1.29 (0.59–2.83)
480 410.6 27 (15.7) 46 (13.9) 1.99 (1.06–3.39) 0.0572
Postmenopausal
p80 p11.5 47 (38.2) 149 (58.0) 1.00 (reference)
p80 411.5 15 (12.2) 30 (11.7) 1.64 (0.77–3.53)
480 p11.5 27 (22.0) 46 (17.9) 1.85 (0.91–3.75)
480 411.5 34 (27.6) 32 (12.4) 3.25 (1.53–6.91) 0.0029
CI¼confidence interval; OR¼odds ratio; WC¼waist circumference.
aWC status and plasma leptin were categorised by the third tertile value in the control group.
bIn addition
to matched variables, odds ratios were also adjusted for body mass index.
Table 2 Breast cancer risk associated with plasma leptin concentrations
Leptin level (ngml
 1) No. of cases (%) No. of controls (%) Matched OR
a (95% CI) Adjusted OR
b (95% CI)
All women
o5.06 68 (22.9) 147 (24.9) 1.00 (reference) 1.00 (reference)
5.06–10.90 124 (41.8) 299 (50.8) 0.93 (0.63–1.38) 0.87 (0.60–1.26)
410.90 105 (35.3) 143 (24.3) 1.63 (1.07–2.49) 1.58 (1.02–2.43)
Ptrend 0.009 0.039
Premenopausal
o4.82 37 (21.5) 83 (25.0) 1.00 (reference) 1.00 (reference)
4.82–10.60 83 (48.3) 168 (50.6) 1.11 (0.68–1.75) 0.99 (0.61–1.61)
410.60 52 (30.2) 81 (24.4) 1.40 (0.83–2.38) 1.63 (0.91–2.89)
Ptrend 0.200 0.103
Postmenopausal
o5.20 28 (22.4) 34 (24.9) 1.00 (reference) 1.00 (reference)
5.20–11.50 47 (37.6) 131 (50.9) 0.78 (0.44–1.37) 0.71 (0.40–1.26)
411.50 50 (40.0) 62 (24.2) 1.69 (0.95–3.06) 1.35 (0.70–2.60)
Ptrend 0.050 0.324
CI¼confidence interval; OR¼odds ratio.
aOdds ratios were matched on the date of enrolment and fasting status.
bIn addition to matched variables, odds ratios were also
adjusted for body mass index and waist circumference.
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scancer is supported by several breast cancer cell models showing
that leptin induces proliferation, survival and anchorage-indepen-
dent growth (Dieudonne et al, 2002; Hu et al, 2002; Yin et al, 2004).
Furthermore, leptin has been found to modulate both oestrogen
synthesis and oestrogen receptor-a activity. For instance, leptin
can upregulate the aromatase gene expression and aromatase
activity in MCF-7 cells, possibly leading to an increased oestrogen
synthesis (Catalano et al, 2004). The relevance of leptin signalling
in breast tumorigenesis is reinforced by the observation that both
leptin and leptin receptor appear to be significantly overexpressed
in breast cancer tissue relative to non-cancer epithelium (Ishikawa
et al, 2004). Despite the large body of in vitro data suggesting the
role of leptin in breast tumorigenesis, there was a large gap
between the mean serum leptin concentration in experiments
(above 100ngml
 1) and in that of epidemiological studies (range:
8–41ngml
 1). Furthermore, regardless of the impact of circula-
ting leptin, recent studies suggest that carcinogenesis could be
induced by an overabundance of locally produced leptin. The
analysis of approximately 300 biopsies revealed that leptin is
overexpressed in breast cancer, whereas it is absent or expressed at
very low levels in normal epithelium or benign tumours (Ishikawa
et al, 2004; Garofalo et al, 2006). Taken together, as leptin has been
associated with cancer risk, but has not been shown to be
oncogenic, further studies are needed to elucidate the levels of
leptin that are needed in human breast tissue for the development
of cancer.
Numerous studies have established that obesity is a risk factor
for breast cancer development (Stoll, 1994; Calle and Thun, 2004).
Specifically, the relationship between obesity assessed by BMI and
breast cancer risk differs between pre- and postmenopausal
women. Body mass index has a strong positive association with
postmenopausal breast cancer and an inverse correlation with
premenopausal cancer risk (van den Brandt et al, 2000). However,
central obesity, mainly measured by the WC or WHR, can increase
breast cancer risk in both premenopausal and postmenopausal
populations (Calle and Thun, 2004). In this study, women with
breast cancer appeared to have high BMI, WC and WHR than
control subjects (Table 1). When stratification by menopausal state
and adjustment for plasma leptin concentration was made, results
suggest that general obesity assessed by BMI and central obesity
measured by WC may both have effects on breast cancer risk.
General obesity has an inverse effect in premenopausal women,
whereas central obesity appears to be positively associated with
increased risk of breast cancer in both pre- and postmenopausal
women. It has been noted that Asian women have greater amounts
of visceral fat – the adipose tissue component most strongly
associated with insulin resistance and lower sex hormone-binding
globulin – for a given waist measurement than Caucasian women
(Lovejoy et al, 1996). As a result, central obesity may have an
important role in breast tumorigenesis in Chinese women (Ng
et al, 1997).
It is worth noting that the association between plasma leptin
concentrations and breast cancer risk remained after adjustment
for obesity indices in this study. In other words, the positive
associations with leptin level were independent of measures of
adiposity (Table 2), and obesity and leptin appear to have
independent roles in breast carcinogenesis (Table 3), as our earlier
observation on adiponectin–breast cancer association (Tian et al,
2007). These results seem to suggest a possibility that other growth
hormones may contribute to obesity–cancer link and mechanisms
other than energy balance may be involved.
The limitations of our study design warrant discussion. There
was only one-time measurement of leptin concentration in this
study. However, a single measurement of circulating leptin levels
appears to reflect an individual’s long-term levels of leptin quite
well, because even in samples taken 4 years apart, intraclass
correlation was high (r¼0.74) (Chu et al, 2001). Meanwhile, any
random error in the assays would tend to underestimate the true
association. In addition, a recent study has shown that leptin was
produced by breast cancer cells (Tessitore et al, 2000), and it is
possible that levels of circulating leptin in subjects for whom
samples were collected subsequent to breast cancer diagnosis and/
or receiving adjuvant treatments may be influenced by the disease
process and/or treatment protocol. Although we restricted our
case–control comparisons to patients whose blood was drawn
before surgery and/or receiving adjuvant therapy, results must be
viewed cautiously. On the other hand, Chen et al (2006b)
compared serum leptin levels in patients with breast cancer,
before surgery and 1 month after surgery, and found no significant
difference between the two groups. This observation suggested that
breast cancer cells produce only small amount of the circulating
levels of leptin and other body adipose tissues might be the major
contributor. The current report has other limitations that the
effects of premenopausal menstrual cycle and postmenopausal
hormone replacement therapy (HRT) on leptin concentrations
were not directly assessed. Circumstantial evidence suggests that
ovarian hormones affect leptin production. Leptin is reported to
fluctuate with the menstrual cycle (Shimizu et al, 1997), and
premenopausal HRT may regulate leptin concentrations (Augoulea
et al, 2005). However, our data indicated that there was no
significant difference in the average duration between the date of
last menstruation and the date of enrolment between premeno-
pausal cases and controls (25.5 vs 26.5 days), and this average
duration was not significantly associated with circulating leptin
levels (the Spearman correlation coefficient in the control group
was 0.0823; P¼0.8361). In addition, our data showed that there
was no significant difference in leptin concentrations between
women who received postmenopausal HRT (51 cases and 145
controls) and those who were non-HRT users (74 cases and 114
controls) (8.78 vs 9.25ngml
 1, P¼0.810). Thus, the phase of
menstrual cycle in premenopausal women and HRT in post-
menopausal women may not affect the case–control comparisons
for leptin concentrations in this study.
In conclusion, the converging lines of evidence from this study
and earlier in vitro studies provide the background biological
context for considering a role for leptin in the pathogenesis of
breast cancer. Further investigation is warranted to confirm and
expand on this empirical finding.
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